Imaging of cerebrovascular pathology in animal models of Alzheimer's disease

Frontiers in Aging Neuroscience

Volumn 6, Issue MAR, 2014, Pages

  Klohs, Jan ^a,b   Rudin, Markus ^a,b   Shimshek, Derya R ^c   Beckmann, Nicolau ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Neuroscience Center Zurich and Division of Neurosurgery   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease (AD); Amyloid beta (A ); Angiography; Cerebral amyloid angiopathy (CAA); Cerebral blood flow (CBF); Magnetic resonance imaging (MRI); Microscopy; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD VESSEL REACTIVITY; BRAIN HEMORRHAGE; BRAIN PERFUSION; EVOKED RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODYNAMICS; IN VIVO STUDY; MICROSCOPY; MORPHOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PROTEIN TRANSPORT; REVIEW; VASCULAR AMYLOIDOSIS;

EID: 84897936619     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00032     Document Type: Review

References (275)

1. Aalto, K., Autio, A., Kiss, E. A., Elima, K., Nymalm, Y., Veres, T. Z., et al. (2011). Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 118, 3725-3733. doi: 10.1182/blood-2010-09-311076
2. Acarin, L., Vela, J. M., González, B., and Castellano, B. (1994). Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding. J. Histochem. Cytochem. 42, 1033-1041. doi: 10.1177/42.8.8027523
3. Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., et al. (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340-9351.
4. Alsop, D. C., Dai, W., Grossman, M., and Detre, J. A. (2010). Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J. Alzheimer Dis. 20, 871-880. doi: 10.3233/JAD-2010-091699
5. Anderson, C. M., and Nedergaard, M. (2003). Astrocyte-mediated control of cerebral microcirculation. Trends Neurosci. 26, 340-344. doi: 10.1016/S0166-2236(03)00141-3
6. Arbel-Ornath, M., Hudry, E., Eikermann-Haerter, K., Hou, S., Gregory, J. L., Zhao, L., et al. (2013). Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. Acta Neuropathol. 126, 353-364. doi: 10.1007/s00401-013-1145-2
7. Ayaz, M., Boikov, A. S., Haacke, E. M., Kido, D. K., and Kirsch, W. M. (2010). Imaging cerebral microbleeds using susceptibility weighted imaging: one step toward detecting vascular dementia. J. Magn. Reson. Imaging 31, 142-148. doi: 10.1002/jmri.22001
8. Badea, A., Gewalt, S., Avants, B. B., Cook, J. J., and Johnson, G. A. (2012). Quantitative mouse brain phenotyping based on single and multispectral MR protocols. Neuroimage 63, 1633-1645. doi: 10.1016/j.neuroimage.2012.07.021
9. Baltes, C., Radzwill, N., Bosshard, S., Marek, D., and Rudin, M. (2009). Micro MRI of the mouse brain using a novel 400 MHz cryogenic quadrature RF probe. NMR Biomed. 22, 834-842. doi: 10.1002/nbm.1396
10. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., et al. (2000). Peripherally administered antibodies against amyloid Aß-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919. doi: 10.1038/78682
11. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. doi: 10.1056/NEJMoa1202753
12. Beach, T. G., Wilson, J. R., Sue, L. I., Newell, A., Poston, M., Cisneros, R., et al. (2007). Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 113, 13-21. doi: 10.1007/s00401-006-0136-y
13. Beckmann, N. (2000). High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magn. Reson. Med. 44, 252-258. doi: 10.1002/1522-2594(200008)44:2<252::AID-MRM12>3.0.CO;2-G
14. Beckmann, N. (2011). Probing cerebrovascular alterations in Alzheimer's disease using MRI: from transgenic models to patients. Curr. Med. Imag. Rev. 7, 51-61. doi: 10.2174/157340511794653531
15. Beckmann, N., Cannet, C., Babin, A. L., Blé, F. X., Zurbruegg, S., Kneuer, R., et al. (2009). In vivo visualization of macrophage infiltration and activity in inflammation using MRI. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 272-298. doi: 10.1002/wnan.16
16. Beckmann, N., Gérard, C., Abramowski, D., Cannet, C., and Staufenbiel, M. (2011). Non-invasive MRI detection of cerebral amyloid angiopathy related microvascular alterations utilizing superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Aß immunotherapy. J. Neurosci. 31, 1023-1031. doi: 10.1523/JNEUROSCI.4936-10.2011
17. Beckmann, N., Schuler, A., Mueggler, T., Meyer, E. P., Wiederhold, K. H., Staufenbiel, M., et al. (2003). Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J. Neurosci. 23, 8453-8459.
18. Beckmann, N., Stirnimann, R., and Bochelen, D. (1999). High resolution magnetic resonance angiography of the mouse brain: application to murine focal cerebral ischemia models. J. Magn. Reson. 140, 442-450. doi: 10.1006/jmre.1999.1864
19. Bell, R. D., and Zlokovic, B. V. (2009). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113. doi: 10.1007/s00401-009-0522-3
20. Biffi, A., and Greenberg, S. M. (2011). Cerebral amyloid angiopathy: a systematic review. J. Clin. Neurol. 7, 1-9. doi: 10.3988/jcn.2011.7.1.1
21. Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2005). Intraneuronal abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688. doi: 10.1016/j.neuron.2005.01.040
22. Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S. M., Hoffmann, N., Mitteregger, G., et al. (2010). Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS ONE 5:e15477. doi: 10.1371/journal.pone.0015477
23. Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., and Planche, M. (2003). Time sequence of maturation of dystrophic neurites associated with Ab deposits in APP/PS1 transgenic mice. Exp. Neurol. 184, 247-263. doi: 10.1016/S0014-4886(03)00252-8
24. Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., and Pickering, R. M. (2008). Consequence of A{beta} immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310. doi: 10.1093/brain/awn261
25. Bornebroek, M., De Jonghe, C., Haan, J., Kumar-Singh, S., Younkin, S., Roos, R., et al. (2003). Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol. Dis. 14, 619-623. doi: 10.1016/j.nbd.2003.08.019
26. Bosshard, S. C., Baltes, C., Wyss, M. T., Mueggler, T., Weber, B., and Rudin, M. (2010). Assessment of brain responses to innocuous and noxious electrical forepaw stimulation in mice using BOLD fMRI. Pain 151, 655-663. doi: 10.1016/j.pain.2010.08.025
27. Boucsein, C., Kettenmann, H., and Nolte, C. (2000). Electrophysiological properties of microglial cells in normal and pathologic rat brain slices. Eur. J. Neurosci. 12, 2049-2058. doi: 10.1046/j.1460-9568.2000.00100.x
28. Braakman, N., Matysik, J., van Duinen, S. G., Verbeek, F., Schliebs, R., De Groot, H. J., et al. (2006). Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 24, 530-536. doi: 10.1002/jmri.20675
29. Buee, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., and Morrison, J. H. (1994). Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. 87, 469-480. doi: 10.1007/BF00294173
30. Burgold, S., Bittner, T., Dorostkar, M. M., Kieser, D., Fuhrmann, M., Mitteregger, G., et al. (2011). In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 121, 327-335. doi: 10.1007/s00401-010-0787-6
31. Busche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., et al. (2012). Critical role of soluble amyloid-ß for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 109, 8740-8745. doi: 10.1073/pnas.1206171109
32. Busche, M. A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K. H., and Haass, C. (2008). Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686-1689. doi: 10.1126/science.1162844
33. Calcinaghi, N., Wyss, M. T., Jolivet, R., Singh, A., Keller, A. L., Winnik, S., et al. (2013). Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. Stroke 44, 1957-1964. doi: 10.1161/STROKEAHA.111.000185
34. Calhoun, M. E., Wiederhold, K. H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., et al. (1998). Neuron loss in APP transgenic mice. Nature 395, 755-756. doi: 10.1038/27351
35. Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K. H., et al. (1999). Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U.S.A. 96, 14088-14093. doi: 10.1073/pnas.96.24.14088
36. Casas, C., Sergeant, N., Itier, J. M., Blanchard, V., Wirths, O., van der Kolk, N., et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289-1300. doi: 10.1016/S0002-9440(10)63388-3
37. Caserta, M. T., Caccioppo, D., Lapin, G. D., Ragin, A., and Groothuis, D. R. (1998). Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J. Neuropsychiatry Clin. Neurosci. 10, 78-84.
38. Chao, L. L., Buckleys, S. T., Kornak, J., Schuff, N., Madison, C., Yaffe, K., et al. (2010). ASL, perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis. Assoc. Disord. 24, 19-27. doi: 10.1097/WAD.0b013e3181b4f736
39. Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., et al. (2000). A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975-979. doi: 10.1038/35046031
40. Chen, J. J., Rosas, H. D., and Salat, D. H. (2011a). Age-associated reductions in cerebral blood flow are independent from regional atrophy. Neuroimage 55, 468-478. doi: 10.1016/j.neuroimage.2010.12.032
41. Chen, Y., Wolk, D. A., Reddin, J. S., Korczykowski, M., Martinez, P. M., and Musiek, E. S. (2011b). Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 77, 1977-1185. doi: 10.1212/WNL.0b013e31823a0ef7
42. Chishti, M. A., Yang, D. S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., et al. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562-21570. doi: 10.1074/jbc. M100710200
43. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., et al. (2003). In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-ß metabolism and half-life. J. Neurosci. 23, 8844-8853.
44. Cohen, R. M., Rezai-Zadeh, K., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I., et al. (2013). A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aß, and frank neuronal loss. J. Neurosci. 33, 6245-6256. doi: 10.1523/JNEUROSCI.3672-12.2013
45. Cordonnier, C., and Van der Flier, W. M. (2011). Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 134, 335-344. doi: 10.1093/brain/awq321
46. Cortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., et al. (2010). Fibrinogen and betaamyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66, 695-709. doi: 10.1016/j.neuron.2010.05.014
47. Daumas, S., Sandin, J., Chen, K. S., Kobayashi, D., Tulloch, J., Martin, S. J., et al. (2008). Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference? Learn. Mem. 15, 625-632. doi: 10.1101/lm.990208
48. Davis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., et al. (2004). Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 20296-20306. doi: 10.1074/jbc. M312946200
49. Deane, R., Sagare, A., and Zlokovic, B. V. (2008). The role of the cell surface LRP and soluble LRP in blood- brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des. 14, 1601-1605. doi: 10.2174/138161208784705487
50. Deane, R., Wu, Z., and Zlokovic, B. V. (2004). RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood- brain barrier. Stroke 35 (11 Suppl. 1), 2628-2631. doi: 10.1161/01.STR.0000143452.85382.d1
51. Dewachter, I., Van Dorpe, J., Smeijers, L., Gilis, M., Kuipéri, C., Laenen, I., et al. (2000). Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J. Neurosci. 20, 6452-6458.
52. Dodart, J. C., Meziane, H., Mathis, C., Bales, K. R., Paul, S. M., and Ungerer, A. (1999). Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci. 113, 982-990. doi: 10.1037/0735-7044.113.5.982
53. Domnitz, S. B., Robbins, E. M., Hoang, A. W., Garcia-Alloza, M., Hyman, B. T., Rebeck, G. W., et al. (2005). Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 64, 588-594. doi: 10.1097/01.jnen.0000171644.00180.fc
54. Dorr, A., Sahota, B., Chinta, L. V., Brown, M. E., Lai, A. Y., Ma, K., et al. (2012). Amyloid-ß-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain 135, 3039-3050. doi: 10.1093/brain/aws243
55. Doyle, L. A., and Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358. doi: 10.1038/sj.onc.1206938
56. Duff, K., Knight, H., Refolo, L. M., Sanders, S., Yu, X., Picciano, M., et al. (2000).Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7, 87-98. doi: 10.1006/nbdi.1999.0279
57. El Tannir El Tayara, N., Delatour, B., Volk, A., and Dhenain, M. (2010). Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease. MAGMA 23, 53-64. doi: 10.1007/s10334-009-0194-y
58. El Tayara Nel, T., Volk, A., Dhenain, M., and Delatour, B. (2007). Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn. Reson. Med. 58, 179-184. doi: 10.1002/mrm.21266
59. Faure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., et al. (2011). Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging 32, 407-418. doi: 10.1016/j.neurobiolaging.2009.03.009
60. Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gutierrez-Gomez, M., Langoi, C. M., et al. (2012). Florbetapir PET analysis of amyloid-b deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross sectional study. Lancet Neurol. 11, 1057-1065. doi: 10.1016/S1474-4422(12)70227-2
61. Frohman, E. M., Frohman, T. C., Gupta, S., De Fougerolles, A., and Van den Noort, S. (1991). Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J. Neurol. Sci. 106, 105-111. doi: 10.1016/0022-510X(91)90202-I
62. Fryer, J. D., Taylor, J. W., Demattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., et al. (2003). Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23, 7889-7896.
63. Fuhrmann, M., Bittner, T., Jung, C. K., Burgold, S., Page, R. M., Mitteregger, G., et al. (2010). Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 13, 411-413. doi: 10.1038/nn.2511
64. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527. doi: 10.1038/373523a0
65. Garcia-Alloza, M., Prada, C., Lattarulo, C., Fine, S., Borrelli, L. A., Betensky, R., et al. (2009). Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem. 109, 1636-1647. doi: 10.1111/j.1471-4159.2009.06096.x
66. Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., et al. (2006). Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516-524. doi: 10.1016/j.nbd.2006.08.017
67. Giesel, F. L., Mehndiratta, A., and Essig, M. (2010). High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur. Radiol. 20, 2461-2474. doi: 10.1007/s00330-010-1805-8
68. Gotz, J., Probst, A., Spillantini, M. G., Schafer, T., Jakes, R., Burki, K., et al. (1995). Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14, 1304-1313.
69. Gregory, J. L., Prada, C. M., Fine, S. J., Garcia-Alloza, M., Betensky, R. A., Arbel-Ornath, M., et al., 2012. Reducing available soluble ß-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. J. Neuropathol. Exp. Neurol. 71, 1009-1017. doi: 10.1097/NEN.0b013e3182729845
70. Grienberger, C., Rochefort, N. L., Adelsberger, H., Henning, H. A., Hill, D. N., Reichwald, J., et al. (2012). Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat. Commun. 3, 774. doi: 10.1038/ncomms1783
71. Hajjar, I., Brown, L., Mack, W. J., and Chui, H. (2012). Impact of angiotensin receptor blockers on Alzheimer's disease pathology in a large brain autopsy series. Arch. Neurol. 69, 1632-1638. doi: 10.1001/archneurol.2012.1010
72. Han, B. H., Zhou, M. L., Abousaleh, F., Brendza, R. P., Dietrich, H. H., Koenigsknecht-Talboo, J., et al. (2008). Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-ß peptide, partial restoration via ?-secretase inhibition. J. Neurosci. 28, 13542-13550. doi: 10.1523/JNEUROSCI.4686-08.2008
73. Han, B. H., Zhou, M. L., Vellimana, A. K., Milner, E., Kim, D. H., Greenberg, J. K., et al. (2011). Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol. Neurodegener. 6, 86. doi: 10.1186/1750-1326-6-86
74. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994
75. Harmsen, M. M., and De Haard, H. J. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13-22. doi: 10.1007/s00253-007-1142-2
76. Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., and Holtzman, D. M. (2005). Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25, 6213-6220. doi: 10.1523/JNEUROSCI.0664-05.2005
77. Havas, D., Hutter-Paier, B., Ubhi, K., Rockenstein, E., Crailsheim, K., Masliah, E., et al. (2011). A longitudinal study of behavioral deficits in an Aß PP transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 25, 231-243. doi: 10.3233/JAD-2011-101866
78. Hébert, F., Grand'maison, M., Ho, M. K., Lerch, J. P., Hamel, E., and Bedell, B. J. (2013). Cortical atrophy and hypoperfusion in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34, 1644-1652. doi: 10.1016/j.neurobiolaging.2012.11.022
79. Hefendehl, J. K., Wegenast-Braun, B. M., Liebig, C., Eicke, D., Milford, D., and Calhoun, M. E. (2011). Long-term in vivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J. Neurosci. 31, 624-629. doi: 10.1523/JNEUROSCI.5147-10.2011
80. Helm, P. J., Ottersen, O. P., and Nase, G. (2009). Analysis of optical properties of the mouse cranium - implications for in vivo multiphoton laser scanning microscopy. J. Neurosci. Methods 178, 316-322. doi: 10.1016/j.jneumeth.2008.12.032
81. Herzig, M. C., Paganetti, P., Staufenbiel, M., and Jucker, M. (2007). BACE1 and mutated presenilin-1 differently modulate Aß40 and Aß42 levels and cerebral amyloidosis in APP dutch transgenic mice. Neurodegener. Dis. 4, 127-135. doi: 10.1159/000101837
82. Herzig, M. C., Eisele, Y. S., Staufenbiel, M., and Jucker, M. (2009). E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. Am. J. Pathol. 174, 722-726. doi: 10.2353/ajpath.2009.080790
83. Herzig, M. C., Van Nostrand, W. E., and Jucker, M. (2006). Mechanism of cerebral ß-amyloid angiopathy: murine and cellular models. Brain Pathol. 16, 40-54. doi: 10.1111/j.1750-3639.2006.tb00560.x
84. Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., et al. (2004). Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954-960. doi: 10.1038/nn1302
85. Higuchi, M. (2009). Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 6, 137-143. doi: 10.2174/156720509787602906
86. Hintersteiner, M., Enz, A., Frey, P., Jaton, A. L., Kinzy, W., Kneuer, R., et al. (2005). In vivo detection of amyloid-ß deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23, 577-583. doi: 10.1038/nbt1085
87. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100. doi: 10.1038/nm0198-097
88. Holtmaat, A., Bonhoeffer, T., Chow, D. K., Chuckowree, J., De Paola, V., Hofer, S. B., et al. (2009). Long-term, high resolution imaging in the mouse neocortex through a chronic cranial window. Nat. Protoc. 4, 1128-1144. doi: 10.1038/nprot.2009.89
89. Hooijmans, C. R., Graven, C., Dederen, P. J., Tanila, H., Van Groen, T., and Kiliaan, A. J. (2007b). Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res. 1181, 93-103. doi: 10.1016/j.brainres.2007.08.063
90. Hooijmans, C. R., Rutters, F., Dederen, P. J., Gambarota, G., Veltien, A., and Van Groen, T. (2007a). Changes in cerebral blood volume and amyloid pathology in aged Alzheimer's APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol. Dis. 28, 16-29. doi: 10.1016/j.nbd.2007.06.007
91. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. doi: 10.1126/science.274.5284.99
92. Hu, S., Yan, P., Maslov, K., Lee, J. M., and Wang, L. V. (2009). Intravital imaging of amyloid plaques in a transgenic mouse model using optical-resolution photoacoustic microscopy. Opt. Lett. 34, 3899-3901. doi: 10.1364/OL.34.003899
93. Hyde, D., De Kleine, R., MacLaurin, S. A., Miller, E., Brooks, D. H., Krucker, T., et al. (2009). Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's disease model. Neuroimage 44, 1304-1311. doi: 10.1016/j.neuroimage.2008.10.038
94. Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., et al. (1999). SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157-161. doi: 10.1038/5715
95. Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., and Borchelt, D. R. (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157-165. doi: 10.1016/S1389-0344(01)00067-3
96. Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., and Jenkins, N. A. (2005). Persistent amyloidosis following suppression of Aß production in a transgenic model of Alzheimer disease. PLoS Med 2:e355. doi 10.1371/journal.pmed.0020355
97. Jantaratnotai, N., Schwab, C., Ryu, J. K., McGeer, P. L., and McLarnon, J. G. (2010). Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. Curr. Alzheimer Res. 7, 625-636. doi: 10.2174/156720510793499039
98. Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of the amyloid formation: implications for the pathogenesis of Alzheimer's diseases. Biochemistry 32, 4693-4697. doi: 10.1021/bi00069a001
99. Jawhara, S., Trawickaa, A., Jenneckensa, C., Bayera, T. A., and Wirths, O. (2012). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aß aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, 196.e29-196.e40. doi: 10.1016/j.neurobiolaging.2010.05.027
100. Jellinger, K. A. (2002). Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 109, 813-836. doi: 10.1007/s007020200068
101. Jensen, J. H., and Chandra, R. (2000). MR imaging of microvasculature. Magn. Reson. Med. 44, 224-230. doi: 10.1002/1522-2594(200008)44:2<224::AID-MRM9>3.0.CO;2-M
102. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000). Statins and the risk of dementia. Lancet 356, 1627-1631. doi: 10.1016/S0140-6736(00)03155-X
103. Johnson, G., Wetzel, S. G., Cha, S., Babb, J., and Tofts, P. S. (2004). Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn. Res. Med. 51, 961-968. doi: 10.1002/mrm.20049
104. Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., et al. (2007). Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62, 229-234. doi: 10.1002/ana.21164
105. Johnson, N. A., Jahng, G. H., Weiner, M. W., Miller, B. L., Chui, H. C., Jagust, W. J., et al. (2005). Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851-859. doi: 10.1148/radiol.2343040197
106. Jonckers, E., Van Audekerke, J., De Visscher, G., Van der Linden, A., and Verhoye, M. (2011). Functional connectivity fMRI of the rodent brain: comparison of functional connectivity networks in rat and mouse PLoS ONE 6:e18876. doi: 10.1371/journal.pone.0018876
107. Kalaria, R. N., Akinyemi, R., and Ihara, M. (2012). Does vascular pathology contribute to Alzheimer changes? J. Neurol. Sci. 322, 141-147. doi: 10.1016/j.jns.2012.07.032
108. Kara, F., Dongen, E. S., Schliebs, R., Buchem, M. A., Groot, H. J., and Alia, A. (2012). Monitoring blood flow alterations in the Tg2576 mouse model of Alzheimer's disease by in vivo magnetic resonance angiography at 17.6 T. Neuroimage 60, 958-966. doi: 10.1016/j.neuroimage.2011.12.055
109. Kassner, A., Roberts, T., Taylor, K., Silver, F., and Mikulis, D. (2005). Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am. J. Neuroradiol. 26, 2213-2217.
110. Kastyak-Ibrahim, M. Z., Di Curzio, D. L., Buist, R., Herrera, S. L., Albensi, B. C., Del Bigio, M. R., et al. (2013). Neurofibrillary tangles and plaques are not accompanied by white matter pathology in aged triple transgenic-Alzheimer disease mice. Magn. Reson. Imaging 31, 1515-1521. doi: 10.1016/j.mri.2013.06.013
111. Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., et al. (2007). Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 27, 627-633. doi: 10.1523/JNEUROSCI.4849-06.2007
112. Kimura, R., and Ohno, M. (2009). Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33, 229-235. doi: 10.1016/j.nbd.2008.10.006
113. Klohs, J., Baltes, C., Princz-Kranz, F., Ratering, D., Nitsch, R. M., Knuesel, I., et al. (2012). Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAß mice. J. Neurosci. 32, 1705-1713. doi: 10.1523/JNEUROSCI.5626-11.2012
114. Klohs, J., Deistung, A., Schweser, F., Grandjean, J., Dominietto, M., Waschkies, C., et al. (2011). Detection of cerebral microbleeds with quantitative susceptibility mapping in the ArcAbeta mouse model of cerebral amyloidosis. J. Cereb. Blood Flow. Metab. 31, 2282-2292. doi: 10.1038/jcbfm.2011.118
115. Klohs, J., Politano, I. W., Deistung, A., Grandjean, J., Drewek, A., Dominietto, M., et al. (2013). Longitudinal assessment of amyloid pathology in transgenic ArcAß mice using multi-parametric magnetic resonance imaging. PLoS ONE 8:e66097. doi: 10.1371/journal.pone.0066097
116. Klohs, J., and Rudin, M. (2011). Unveiling molecular events in the brain by noninvasive imaging. Neuroscientist 17, 539-559. doi: 10.1177/1073858410383433
117. Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., et al. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598-10606. doi: 10.1523/JNEUROSCI.2990-05.2005
118. Knobloch, M., Konietzko, U., Krebs, D. C., and Nitsch, R. M. (2007). Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging 28, 1297-1306. doi: 10.1016/j.neurobiolaging.2006.06.019
119. Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., et al. (2008). Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 28, 14156-14164. doi: 10.1523/JNEUROSCI.4147-08.2008
120. Koutnetsova, E., Klinger, M., Sorger, D., Sabri, O., Grossmann, U., Steinbach, J., et al. (2006). Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int. J. Dev. Neurosci. 24, 187-193. doi: 10.1016/j.ijdevneu.2005.11.011
121. Krstic, D., and Knuesel, I. (2013). Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9, 25-34. doi: 10.1038/nrneurol.2012.236
122. Krucker, T., Schuler, A., Meyer, E. P., Staufenbiel, M., and Beckmann, N. (2004). Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease. Neurol. Res. 26, 507-516. doi: 10.1179/016164104225016281
123. Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., et al. (2007). MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 17, 347-353. doi: 10.1111/j.1750-3639.2007.00075.x
124. Kulic, L., McAfoose, J., Welt, T., Tackenberg, C., Spani, C., Wirth, F., et al. (2012). Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Abeta APP mutation. Transl. Psychiatry 2, e183. doi: 10.1038/tp.2012.109
125. Kumar-Singh, S. (2009). Hereditary and sporadic forms of Aß-cerebrovascular amyloidosis and relevant transgenic mouse models. Int. J. Mol. Sci. 10, 1872-1895. doi: 10.3390/ijms10041872
126. Kumar-Singh, S., Pirici, D., McGowan, E., Serneels, S., Ceuterick, C., Hardy, J., et al. (2005). Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am. J. Pathol. 167, 527-543. doi: 10.1016/S0002-9440(10)62995-1
127. Lau, J. C., Lerch, J. P., Sled, J. G., Henkelman, R. M., Evans, A. C., and Bedell, B. J. (2008). Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neuroimage 42, 19-27. doi: 10.1016/j.neuroimage.2008.04.252
128. Li, N. C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., et al. (2010). Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465. doi: 10.1136/bmj.b5465
129. Li, X. G., Autio, A., Ahtinen, H., Helariutta, K., Liljenbäck, H., and Jalkanen, S. (2013). Translating the concept of peptide labeling with 5-deoxy-5-[18F]fluororibose into preclinical practice: 18F-labeling of Siglec-9 peptide for PET imaging of inflammation. Chem. Commun. (Camb.) 49, 3682-3684. doi: 10.1039/c3cc40738a
130. Lin, W., Abendschein, D. R., Celik, A., Dolan, R. P., Lauffer, R. B., Walovitch, R. C., et al. (1997). Intravascular contrast agent improves magnetic resonance angiography of carotid areries in minipigs. J. Magn. Reson. Imaging 7, 963-971. doi: 10.1002/jmri.1880070605
131. Lobatto, M. E., Fuster, V., Fayad, Z. A., and Mulder, W. J. (2011). Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug. Discov. 10, 835-852. doi: 10.1038/nrd3578
132. Logothetis, N. K., Pauls, J., Augath, M., Trinath, T., and Oeltermann, A. (2001). Neurophysiological investigation of the basis of the fMRI signal. Nature 412, 150-157. doi: 10.1038/35084005
133. Lord, A., Kalimo, H., Eckman, C., Zhang, X. Q., Lannfelt, L., and Nilsson, L. N. (2006). The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 27, 67-77. doi: 10.1016/j.neurobiolaging.2004.12.007
134. Lovasic, L., Bauschke, H., and Janus, C. (2005). Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Genes Brain Behav. 4, 197-208. doi: 10.1111/j.1601-183X.2004.00104.x
135. Luo, F., Rustay, N. R., Ebert, U., Hradil, V. P., Cole, T. B., Llano, D. A., et al. (2012). Characterization of 7-and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 33, 933-944. doi: 10.1016/j.neurobiolaging.2010.08.005
136. Luo, F., Rustay, N. R., Seifert, T., Roesner, B., Hradil, V., Hillen, H., et al. (2010). Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic ice. J. Pharmacol. Exp. Ther. 335, 580-588. doi: 10.1124/jpet.110.172932
137. Luo, F., Seifert, T. R., Edalji, R., Loebbert, R. W., Hradil, V. P., Harlan, J., et al. (2008). Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 155, 263-269. doi: 10.1016/j.neuroscience.2008.04.021
138. Maat-Schieman, M. L., Van Duinen, S. G., Rozemuller, A. J., Haan, J., and Roos, R. A. (1997). Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 273-284. doi: 10.1097/00005072-199703000-00006
139. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968. doi: 10.1523/JNEUROSCI.0673-07.2007
140. Maeda, J., Zhang, M. R., Okauchi, T., Ji, B., Ono, M., Hattori, S., et al. (2011). In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 31, 4720-4730. doi: 10.1523/JNEUROSCI.3076-10.2011
141. Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108. doi: 10.1016/j.neuron.2013.07.037
142. Masamoto, K., and Kanno, I. (2012). Anesthesia and the quantitative evaluation of neurovascular coupling. J. Cereb. Blood Flow. Metab. 32, 1233-1247. doi: 10.1038/jcbfm.2012.50
143. Massaad, C. A., Amin, S. K., Hu, L., Mei, Y., Klann, E., and Pautler, R. G. (2010). Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS ONE 5:e10561. doi: 10.1371/journal.pone.0010561
144. Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., et al. (2003). Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23, 29-33.
145. McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., et al. (2005). Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199. doi: 10.1016/j.neuron.2005.06.030
146. McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H., Phinney, A. L., et al. (2006). Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808. doi: 10.1038/nm1423
147. McLean, D., Cooke, M. J., Albay, R. 3rd., Glabe, C., and Shoichet, M. S. (2013). Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-ß in TgCRND8 mice. ACS Chem. Neurosci. 4, 613-623. doi: 10.1021/cn300226q
148. Mellin, A. F., Cofer, G. P., Smith, B. R., Suddarth, S. A., Hedlund, L. W., and Johnson, G. A. (1994). Three dimensional magnetic resonance microangiography of rat neurovasculature. Mag. Res. Med. 32, 199-205. doi: 10.1002/mrm.1910320208
149. Melnikova, T., Fromholt, S., Kim, H., Lee, D., Xu, G., Price, A., et al. (2013). Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J. Neurosci. 33, 3765-3779. doi: 10.1523/JNEUROSCI.4251-12.2013
150. Merlini, M., Meyer, E. P., Ulmann-Schuler, A., and Nitsch, R. M. (2011). Vascular ß-amyloid and early astroctye alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAß mice. Acta Neuropathol. 122, 293-311. doi: 10.1007/s00401-011-0834-y
151. Meyer, E. P., Ulmann-Schuler, A., Staufenbiel, M., and Krucker, T. (2008). Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 105, 3587-3592. doi: 10.1073/pnas.0709788105
152. Miao, J., Xu, F., Davis, J., Otte-Holler, I., Verbeek, M. M., and Van Nostrand, W. E. (2005). Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am. J. Pathol. 167, 505-515. doi: 10.1016/S0002-9440(10)62993-8
153. Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492. doi: 10.1074/jbc.274.10.6483
154. Montagne, A., Gauberti, M., Macrez, R., Jullienne, A., Briens, A., Raynaud, J. S., et al. (2012). Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage 63, 760-770. doi: 10.1016/j.neuroimage.2012.07.018
155. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., et al. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058.
156. Mueggler, T., Baumann, D., Rausch, M., Staufenbiel, M., and Rudin, M. (2003). Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 23, 8231-8236.
157. Mueggler, T., Sturchler-Pierrat, C., Baumann, D., Rausch, M., Staufenbiel, M., and Rudin, M. (2002). Compromized hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 22, 7218-7224.
158. Nabuurs, R. J., Rutgers, K. S., Welling, M. M., Metaxas, A., De Backer, M. E., Rotman, M., et al. (2012). In vivo detection of amyloid-b deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease. PLoS ONE 7:e38284. doi: 10.1371/journal.pone.0038284
159. Nagata, K., Maruya, H., Yuya, H., Terashi, H., Mito, Y., Kato, H., et al. (2000). Can PET data differentiate Alzheimer's disease from vascular dementia? Ann. N.Y. Acad. Sci. 903, 252-261. doi: 10.1111/j.1749-6632.2000.tb06375.x
160. Nilsson, L. N., Arendash, G. W., Leighty, R. E., Costa, D. A., Low, M. A., Garcia, M. F., et al. (2004). Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging 25, 1153-1167. doi: 10.1016/j.neurobiolaging.2003.12.011
161. Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002). Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283, H315-H323. doi: 10.1152/ajpheart.00022.2002
162. Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., and Iadecola, C. (2001). Abeta-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281, H2417-H2424.
163. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal ß-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140. doi: 10.1523/JNEUROSCI.1202-06.2006
164. Oberg, J., Spenger, C., Wang, F. H., Andersson, A., Westman, E., Skoglund, P., et al. (2008). Age related changes in brain metabolites observed by H-1 MRS in APP/PS1 mice. Neurobiol. Aging 29, 1423-1433. doi: 10.1016/j.neurobiolaging.2007.03.002
165. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P., and LaFerla, F. M. (2003a). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24, 1063-1070. doi: 10.1016/j.neurobiolaging.2003.08.012
166. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., and Kayed, R. (2003b). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. doi: 10.1016/S0896-6273(03)00434-3
167. Ogawa, S., Tank, D. W., Menon, R., Ellermann, J. M., Kim, S. G., and Merkle, H. (1992). Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc. Nat. Acad. Sci. U.S.A. 89, 5951-5955. doi: 10.1073/pnas.89.13.5951
168. Okamoto, Y., Yamamoto, T., Kalaria, R. N., Senzaki, H., Maki, T., Hase, Y., et al. (2012). Cerebral hypoperfusion accelaretes cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol. 123, 381-394. doi: 10.1007/s00401-011-0925-9
169. Okamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero-Tavoletti, M., et al. (2012). Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 54, 1420-1427. doi: 10.2967/jnumed.112.117341
170. Okamura, N., Suemoto, T., Shiomitsu, T., Suzuki, M., Shimadzu, H., Akatsu, H., et al. (2004). A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J. Mol. Neurosci. 24, 247-255. doi: 10.1385/JMN:24:2:247
171. O'Leary, T. P., and Brown, R. E. (2009). Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 201, 120-127. doi: 10.1016/j.bbr.2009.01.039
172. Owen, D. R., Lindsay, A. C., Choudhury, R. P., and Fayad, Z. A. (2011). Imaging of atherosclerosis. Annu. Rev. Med. 62, 25-40. doi: 10.1146/annurev-med-041709-133809
173. Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., et al. (2003). Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25, 642-651. doi: 10.1179/016164103101201940
174. Paris, D., Town, T., Mori, T., Parker, T. A., Humphrey, J., and Mullan, M. (2000). Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging 21, 183-197. doi: 10.1016/S0197-4580(00)82162-4
175. Park, L., Zhou, P., Koizumi, K., El Jamal, S. E., Previti, M. L., Van Nostrand, W. E., et al. (2013). Brain and circulating levels of Aß 1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke 44, 198-204. doi: 10.1161/STROKEAHA.112.670976
176. Park, L., Zhou, P., Pistick, R., Capone, C., Anrather, J., Norris, E. H., et al. (2008). Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 105, 1347-1352. doi: 10.1073/pnas.0711568105
177. Paul, J., Strickland, S., and Melchor, J. P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204, 1999-2008. doi: 10.1084/jem.20070304
178. Perez-Cruz, C., Nolte, M. W., Van Gaalen, M. M., Rustay, N. R., Termont, A., Tanghe, A., et al. (2011). Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J. Neurosci. 31, 3926-3934. doi: 10.1523/JNEUROSCI.6142-10.2011
179. Perez-Torres, C. J., Reynolds, J. O., and Pautler, R. G. (2014). Use of magnetization transfer contrast MRI to detect early molecular pathology in Alzheimer's disease. Magn. Reson. Med. 71, 333-338. doi: 10.1002/mrm.24665
180. Pettersen, J. A., Sathiyamoorthy, G., Gao, F. Q., Szilagyi, G., Nadkarni, N. K., St. George-Hyslop, P., et al. (2008). Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia study. Arch. Neurol. 65, 790-795. doi: 10.1001/archneur.65.6.790
181. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., et al. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298, 1379. doi: 10.1126/science.1078259
182. Poduslo, J. F., Hultman, K. L., Curran, G. L., Preboske, G. M., Chamberlain, R., Marjañska, M., et al. (2011). Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid ß protein antibody-coated nanoparticles. J. Neuropathol. Exp. Neurol. 70, 653-661. doi: 10.1097/NEN.0b013e318225038c
183. Poisnel, G., Herard, A. S., El Tannir El Tayara, N., Bourrin, E., Vol, A., Kober, F., et al. (2012). Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol. Aging 33, 1995-2005. doi: 10.1016/j.neurobiolaging.2011.09.026
184. Prada, C. M., Garcia-Alloza, M., Betensky, R. A., Zhang-Nunes, S. X., Greenberg, S. M., Bacskai, B. J., et al. (2007). Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J. Neurosci. 27, 1973-1980. doi: 10.1523/JNEUROSCI.5426-06.2007
185. Princz-Kranz, F. L., Mueggler, T., Knobloch, M., Nitsch, R. M., and Rudin, M. (2010). Vascular response to acetazolamide decreases as a function of age in the arcA beta mouse model of cerebral amyloidosis. Neurobiol. Dis. 40, 284-292. doi: 10.1016/j.nbd.2010.06.002
186. Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., et al. (2006). Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940-946. doi: 10.1038/sj.embor.7400784
187. Rausch, M., Scheffler, K., Rudin, M., and Radü, E. W. (2000). Analysis of input functions from different arterial branches with gamma variate functions and cluster analysis for quantitative blood volume measurements. Magn. Reson. Imaging 18, 1235-1243. doi: 10.1016/S0730-725X(00)00219-8
188. Redwine, J. M., Kosofsky, B., Jacobs, R. E., Games, D., Reilly, J. F., Morrison, J. H., et al. (2003). Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. U.S.A. 100, 1381-1386. doi: 10.1073/pnas.242746599
189. Reese, T., Bochelen, D., Sauter, A., Beckmann, N., and Rudin, M. (1999). Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed. 12, 189-196.
190. Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., et al. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11, 1048-1056. doi: 10.1016/S1474-4422(12)70228-4
191. Richards, J. G., Higgins, G. A., Ouagazzal, A. M., Ozmen, L., Kew, J. N., Bohrmann, B., et al. (2003). PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 23, 8989-9003.
192. Robbins, E. M., Betensky, R. A., Domnitz, S. B., Purcell, S. M., Garcia-Alloza, M., Greenberg, C., et al. (2006). Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J. Neurosci. 26, 365-371. doi: 10.1523/JNEUROSCI.3854-05.2006
193. Rockenstein, E., Mallory, M., Mante, M., Sisk, A., and Masliaha, E. (2001). Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res. 66, 573-582. doi: 10.1002/jnr.1247
194. Roher, A. E., Esh, C., Kokjohn, T. A., Kalback, W., Luehrs, D. C., Seward, J. D., et al. (2003). Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23, 2055-2062. doi: 10.1161/01.ATV.0000095973.42032.44
195. Rojas, S., Herance, J. R., Gispert, J. D., Abad, S., Torrent, E., Jiménez, X., et al. (2013). In vivo evaluation of amyloid deposition and brain glucose metabolism of 5xFAD mice using positron emission tomography. Neurobiol. Aging 34, 1790-1798. doi: 10.1016/j.neurobiolaging.2012.12.027
196. Rönnbäck, A., Sagelius, H., Bergstedt, K. D., Näslund, J., Westermark, G. T., Winblad, B., et al. (2012). Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol. Aging 33, 831.e11-831.e19. doi: 10.1016/j.neurobiolaging.2011.07.012
197. Rönnbäck, A., Zhu, S., Dillner, K., Aoki, M., Lilius, L., Näslund, J., et al. (2011). Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol. Aging 32, 280-292. doi: 10.1016/j.neurobiolaging.2009.02.021
198. Rupp, N. J., Wegenast-Braun, B. M., Radde, R., Calhoun, M. E., and Jucker, M. (2011). Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging 32, 2324.e2321-2324.e2326. doi: 10.1016/j.neurobiolaging.2010.08.014
199. Rutgers, K. S., Van Remoortere, A., van Buchem, M. A., Verrips, C. T., Greenberg, S. M., and Bacskai, B. J. (2009). Differential recognition of vascular and parenchymal beta amyloid deposition. Neurobiol. Aging 32, 1774-1783. doi: 10.1016/j.neurobiolaging.2009.11.012
200. Sadowski, M., Pankiewicz, J., Scholtzova, H., Yong, J., Quartermain, D., Jensen, C. H., et al. (2004). Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 63, 418-428.
201. Sanganahalli, B. G., Herman, P., Behar, K. L., Blumenfeld, H., Rothman, D. L., and Hyder, F. (2013). Functional MRI and neural responses in a rat model of Alzheimer's disease. Neuroimage 79, 404-411. doi: 10.1016/j.neuroimage.2013.04.099
202. SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. doi: 10.1126/science.1113694
203. Savonenko, A., Xu, G. M., Melnikova, T., Morton, J. L., Gonzales, V., Wong, M. P., et al. (2005). Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18, 602-617. doi: 10.1016/j.nbd.2004.10.022
204. Schmitz, C., Rutten, B. P., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., et al. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164, 1495-1502. doi: 10.1016/S0002-9440(10)63235-X
205. Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., et al. (2008). Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28, 6787-6793. doi: 10.1523/JNEUROSCI.2377-07.2008
206. Schulz, K., Sydekum, E., Krueppel, R., Engelbrecht, C. J., Schlegel, F., Schröter, A., et al. (2012). Simultaneous BOLD fMRI and fiber-optic calcium recording in rat neocortex. Nat. Methods 9, 597-602. doi: 10.1038/nmeth.2013
207. Schwendele, B., Brawek, B., Hermes, M., and Garaschuk, O. (2012). High-resolution in vivo imaging of microglia using a versatile nongenetically encoded marker. Eur. J. Immunol. 42, 2187-2196. doi: 10.1002/eji.201242436
208. Shibata, M., Ohtani, R., Ihara, M., and Tomimoto, H. (2004). White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35, 2598-2603. doi: 10.1161/01.STR.0000143725.19053.60
209. Smith, K. D., Kallhoff, V., Zheng, H., and Pautler, R. G. (2007). In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 35, 1401-1408. doi: 10.1016/j.neuroimage.2007.01.046
210. Snellman, A., Lopez-Picon, F. R., Rokka, J., Salmona, M., Forloni, G., Scheinin, M., et al. (2013). Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J. Nucl. Med. 54, 1434-1441. doi: 10.2967/jnumed.112.110163
211. Snowdon, D. A. (2003). Nun study, healthy aging and dementia: findings from the Nun study. Ann. Intern. Med. 139(5 Pt 2), 450-454. doi: 10.7326/0003-4819-139-5_Part_2-200309021-00014
212. Song, S. K., Kim, J. H., Lin, S. J., Brendza, R. P., and Holtzman, D. M. (2004). Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis. 15, 640-647. doi: 10.1016/j.nbd.2003.12.003
213. Sparks, D. L., Sabbagh, M., Connor, D., Soares, H., Lopez, J., Stankovic, G., et al. (2006). Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 78-86. doi: 10.1111/j.1600-0404.2006.00689.x
214. Spencer, N. G., Bridges, L. R., Elderfield, K., Amir, K., Austen, B., and Howe, F. A. (2013). Quantitative evaluation of MRI and histological characteristics of the 5xFAD Alzheimer mouse brain. Neuroimage 76, 108-115. doi: 10.1016/j.neuroimage.2013.02.071
215. Sperling, R. A., Jack, C. R. Jr., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., et al. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367-385. doi: 10.1016/j.jalz.2011.05.2351
216. Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., et al. (2010). Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 5:e9979. doi: 10.1371/journal.pone.0009979
217. Starmans, L. W., Van Duijnhoven, S. M., Rossin, R., Aime, S., Daemen, M. J., Nicolay, K., et al. (2013). SPECT imaging of fibrin using fibrin-binding peptides. Contrast Media Mol. Imaging 8, 229-237. doi: 10.1002/cmmi.1521
218. Starr, J. M., Farrall, A. J., Armitage, P., McGurn, B., and Wardlaw, J. (2009). Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res. 171, 232-241. doi: 10.1016/j.pscychresns.2008.04.003
219. Stover, K. R., and Brown, R. E. (2012). Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 231, 75-85. doi: 10.1016/j.bbr.2012.02.044
220. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94, 13287-13292. doi: 10.1073/pnas.94.24.13287
221. Sun, S. W., Song, S. K., Harms, M. P., Lin, S. J., Holtzman, D. M., Merchant, K. M., et al. (2005). Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp. Neurol. 191, 77-85. doi: 10.1016/j.expneurol.2004.09.006
222. Takano, T., Han, X., Deane, R., Zlokovic, B., and Nedergaard, M. (2007). Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann. N.Y. Acad. Sci. 1097, 40-50. doi: 10.1196/annals.1379.004
223. Takano, T., Tian, G. F., Peng, W., Lou, N., Libionka, W., and Han, X. (2006). Astrocyte-mediated control of cerebral blood flow. Nat. Neurosci. 9, 260-267. doi: 10.1038/nn1623
224. Takeda, S., Sato, N., Takeuchi, D., Kurinami, H., Shinohara, M., Niisato, K., et al. (2009). Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54, 1345-1352. doi: 10.1161/HYPERTENSIONAHA.109.138586
225. Talagala, S. L., Jungreis, C. A., Kanal, E., Meyers, S. P., Foo, T. K. F., Rubin, R. A., et al. (1995). Fast three-dimensional time-of-flight MR angiography of the intracranial vasculature. J. Magn. Reson. Imaging 5, 317-323. doi: 10.1002/jmri.1880050316
226. Tanghe, A., Termont, A., Merchiers, P., Schilling, S., Demuth, H. U., Scrocchi, L., et al. (2010). Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. Int. J. Alzheimers Dis. 2010:pii: 417314. doi: 10.4061/2010/417314
227. Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., et al. (2009). Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. U.S.A. 106, 4501-4506. doi: 10.1073/pnas.0813404106
228. Thal, D. R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S., and Beckmann, N. (2009). Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging 30, 1936-1948. doi: 10.1016/j.neurobiolaging.2008.01.017
229. Thal, D. R., Griffin, W. S., and Braak, H. (2008b). Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J. Cell. Mol. Med. 12, 1848-1862. doi: 10.1111/j.1582-4934.2008.00411.x
230. Thal, D. R., Griffin, W. S., De Vos, R. A., and Ghebremedhin, E. (2008a). Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 115, 599-609. doi: 10.1007/s00401-008-0366-2
231. Thanopoulou, K., Fragkouli, A., Stylianopoulou, F., and Georgopoulos, S. (2010). Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl. Acad. Sci. U.S.A. 107, 20816-20821. doi: 10.1073/pnas.1005888107
232. Tofts, P. S., and Kernode, A. G. (1991). Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn. Reson. Med. 17, 357-367. doi: 10.1002/mrm.1910170208
233. Tong, X. K., Lecrux, C., and Hamel, E. (2012). Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J. Neurosci. 32, 4705-4715. doi: 10.1523/JNEUROSCI.0169-12.2012
234. Tong, X. K., Nicolakakis, N., KocharyanA., and Hamel, E. (2005). Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25, 11165-11174. doi: 10.1523/JNEUROSCI.4031-05.2005
235. Tropres, I., Grimault, S., Vaeth, A., Grillon, E., Julien, C., Payen, J. F., et al. (2001). Vessel size imaging. Magn. Reson. Med. 45, 397-408. doi: 10.1002/1522-2594(200103)45:3<397::AID-MRM1052>3.0.CO;2-3
236. van Assema, D. M., Lubberink, M., Bauer, M., Van der Flier, W. M., Schuit, R. C., Windhorst, A. D., et al. (2012). Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135(Pt 1), 181-189. doi: 10.1093/brain/awr298
237. van Dorpe, J., Smeijers, L., Dewachter, I., Nuyens, D., Spittaels, K., Van Den Haute, C., et al. (2000). Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 157, 1283-1298. doi: 10.1016/S0002-9440(10)64644-5
238. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., and Van der Linden, A. (2005). Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53, 607-613. doi: 10.1002/mrm.20385
239. Venneti, S., Lopresti, B. J., Wang, G., Hamilton, R. L., Mathis, C. A., and Klunk, W. E. (2009). PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 30, 1217-1226. doi: 10.1016/j.neurobiolaging.2007.11.005
240. Villringer, A., Rosen, B. R., Bellieau, J. W., Ackerman, J. L., Lauffer, R. B., Buxton, R. B., et al. (1998). Dynamic imaging with lanthanide chelates in normal brain contrast due to magnetic susceptibility effects. Magn. Res. Med. 6, 164-174. doi: 10.1002/mrm.1910060205
241. Vinters, H. V. (1987). Cerebral amyloid angiopathy. A critical review. Stroke 18, 311-324. doi: 10.1161/01.STR.18.2.311
242. Vinters, H. V., Natté, R., Maat-Schieman, M. L., Van Duinen, S. G., Hegeman-Kleinn, I., Welling-Graafland, C., et al. (1998). Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). Acta Neuropathol. (Berl.) 95, 235-244. doi: 10.1007/s004010050793
243. Vom Berg, J., Prokop, S., Miller, K. R., Obst, J., Kalin, R. E., Lopategui-Cabezas, I., et al. (2012). Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18, 1812-1819. doi: 10.1038/nm.2965
244. Vromman, A., Trabelsi, N., Rouxel, C., Béréziat, G., Limon, I., and Blaise, R. (2013). ß-Amyloid context intensifies vascular smooth muscle cells induced inflammatory response and de-differentiation. Aging Cell 12, 358-369. doi: 10.1111/acel.12056
245. Wang, F. H., Appelkvist, P., Klason, T., Gissberg, O., Bogstedt, A., Eliason, K., et al. (2012c). Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI. Eur. J. Neurosci. 36, 3165-3172. doi: 10.1111/j.1460-9568.2012.08258.x
246. Wang, H., He, J., Zhang, R., Zhu, S., Wang, J., Kong, L., et al. (2012a). Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease. Behav. Brain Res. 233, 237-243. doi: 10.1016/j.bbr.2012.05.007
247. Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., et al. (2007). Valsartan lowers brain b-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393-3402. doi: 10.1172/JCI31547
248. Wang, M., Iliff, J. J., Liao, Y., Chen, M. J., Shinseki, M. S., Venkataraman, A., et al. (2012b). Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts. J. Neurosci. 32, 17948-17960. doi: 10.1523/JNEUROSCI.1860-12.2012
249. Washida, K., Ihara, M., Nishio, K., Fujita, Y., Maki, T., Yamada, M., et al. (2010). Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 41, 1798-1806. doi: 10.1161/STROKEAHA.110.583948
250. Watts, J. C., Giles, K., Grillo, S. K., Lemus, A., DeArmond, S. J., and Prusiner, S. B. (2011). Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 108, 2528-2533. doi: 10.1073/pnas.1019034108
251. Wegiel, J., Imaki, H., Wang, K. C., Wegiel, J., and Rubenstein, R. (2004). Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Brain Res. 1022, 19-29. doi: 10.1016/j.brainres.2004.06.058
252. Weidensteiner, C., Metzger, F., Bruns, A., Bohrmann, B., Kuennecke, B., and von Kienlin, M. (2009). Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: comprehensive phenotyping of vascular and tissular parameters by MRI. Magn. Reson. Med. 62, 35-45. doi: 10.1002/mrm.21985
253. Weiss, C., Venkatasubramanian, P. N., Aguado, A. S., Power, J. M., Tom, B. C., Li, L., et al. (2002). Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. Neurobiol. Dis. 11, 425-433. doi: 10.1006/nbdi.2002.0555
254. Weissleder, R., Elizondo, G., Wittenberg, J., Rabito, C., Bengele, H., and Josephson, L. (1990). Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175, 489-493.
255. Weller, R. O. (1998). Cerebral amyloid angiopathy: amyloid ß accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153, 725-733. doi: 10.1016/S0002-9440(10)65616-7
256. Weller, R. O., Boche, D., and Nicoll, J. A. (2009). Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 118, 87-102. doi: 10.1007/s00401-009-0498-z
257. Wilcock, D. M., Alamed, J., Gottschall, P. E., Grimm, J., Rosenthal, A., Pons, J., et al. (2006). Deglycosylated anti-amyloid-ß antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 26, 5340-5346. doi: 10.1523/JNEUROSCI.0695-06.2006
258. Wilcock, D. M., Morgan, D., Gordon, M. N., Taylor, T. L., Ridnour, L. A., Wink, D. A., et al. (2011). Activation of matrix metalloproteinases following anti-Aß immunotherapy; implications for microhemorrhage occurrence. J. Neuroinflammation 8, 115. doi: 10.1186/1742-2094-8-115
259. Wilcock, D. M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., and Alamed, J. (2004b). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 6144-6151. doi: 10.1523/JNEUROSCI.1090-04.2004
260. Wilcock, D. M., Rojiani, A., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., et al. (2004a). Passive immunotherapy against Aß in aged APP transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1, 24. doi: 10.1186/1742-2094-1-24
261. Williams, D. S., Detre, J. A., Leigh, J. S., and Koretsky, A. P. (1992). Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc. Natl. Acad. Sci. U.S.A. 89, 212-216. doi: 10.1073/pnas.89.1.212
262. Winkler, D. T., Bondolfi, L., Herzig, M. C., Jann, L., Calhoun, M. E., Wiederhold, K. H., et al. (2001). Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21, 1619-1627.
263. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443. doi: 10.1001/archneur.57.10.1439
264. Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., et al. (2010). In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51, 913-920. doi: 10.2967/jnumed.109.069088
265. Woolley, M. L., and Ballard, T. M. (2005). Age-related impairments in operant DMTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease. Behav. Brain Res. 161, 220-228. doi: 10.1016/j.bbr.2005.02.007
266. Wright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., et al. (2013). Neuroinflammation and neuronal loss precede Aß plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS ONE 8:e59586. doi: 10.1371/journal.pone.0059586
267. Wu, E. X., Tang, H., Asai, T., and Yan, S. D. (2004). Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci. Lett. 365, 223-227. doi: 10.1016/j.neulet.2004.05.004
268. Wunder, A., and Klohs, J. (2008). Optical imaging of vascular pathophysiology. Basic Res. Cardiol. 103, 182-190. doi: 10.1007/s00395-008-0712-5
269. Wunder, A., Klohs, J., and Dirnagl, U. (2009). Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience 158, 1161-1173. doi: 10.1016/j.neuroscience.2008.10.005
270. Xiong, H., Callaghan, D., Jones, A., Bai, J., Rasquinha, I., Smith, C., et al. (2009). ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J. Neurosci. 29, 5463-5475. doi: 10.1523/JNEUROSCI.5103-08.2009
271. Xu, F., Grande, A. M., Robinson, J. K., Previti, M. L., Vasek, M., Davis, J., et al. (2007). Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 146, 98-107. doi: 10.1016/j.neuroscience.2007.01.043
272. Yang, J., Ji, Y., Mehta, P., Bates, K. A., Sun, Y., and Wisniewski, T. (2011). Blocking the ApolipoproteinE/Amyloid-b interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J. Alzheimers Dis. 24, 269-285. doi: 10.3233/JAD-2011-101401
273. Yarchoan, M., Xie, S. X., Kling, M. A., Toledo, J. B., Wolk, D. A., Lee, E. B., et al. (2012). Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 135, 3749-3756. doi: 10.1093/brain/aws271
274. Zha, Z., Choi, S. R., Ploessl, K., Lieberman, B. P., Qu, W., Hefti, F., et al. (2011). Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aß plaques in cerebral amyloid angiopathy (CAA). J. Med. Chem. 54, 8085-8098. doi: 10.1021/jm2009106
275. Zhang, W., Mojsilovic-Petrovic, J., Andrade, M. F., Zhang, H., Ball, M., and Stanimirovic, D. B. (2003). Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17, 2085-2087. doi: 10.1096/fj.02-1131fje